Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 12/20 | 0.50 |
| ▸ | CASP6 | P55212 | 10/20 | 0.50 |
| ▸ | CASP8 | Q14790 | 10/20 | 0.50 |
| ▸ | CASP1 | P29466 | 3/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800767 | 0.88 | RECQL (0.52) | CASP3CASP6CASP8RECQLSMN1; SMN2 | |
| SCHEMBL7179680 | 0.84 | RECQL (0.55) | CASP3CASP6CASP8RECQLSMN1; SMN2 | |
| SCHEMBL6801541 | 0.84 | CASP1 (0.59) | CASP3CASP6CASP8CASP1SMN1; SMN2 | |
| SCHEMBL6281724 | 0.84 | CASP1 (0.59) | CASP3CASP6CASP8CASP1SMN1; SMN2 | |
| SCHEMBL6801048 | 0.81 | CASP3 (0.52) | CASP3CASP6CASP8CASP1TXNRD1 | |
| SCHEMBL7179607 | 0.80 | CASP3 (0.47) | CASP3CASP6CASP8TXNRD1 | |
| SCHEMBL22361824 | 0.80 | MAPT (0.56) | CASP1 | |
| SCHEMBL19418905 | 0.80 | MAPT (0.56) | CASP1 | |
| SCHEMBL6801811 | 0.76 | ITGAL (0.47) | CASP3CASP6CASP8TDP1 | |
| SCHEMBL6802721 | 0.75 | CASP3 (0.55) | CASP3CASP6CASP8CASP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009923-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | DOLLE ROLAND E (US) | 2004-01-15 | — | — | US | claimed |
| US-6576614-B1 | Administering methyl ketones or closed hemiketal derivatives of aspartic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2003-06-10 | — | — | US | claimed |
| US-5985838-A | TREATING INFECTIOUS DISEASE, RESPIRATORY DISEASE, INFLAMMATORY CONDITIONS, IMMUNE-BASED DISEASE, AUTO-IMMUNE DISEASE, BONE DISEASE, AND TUMORS | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | claimed |
| EP-0623592-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | STERLING WINTHROP INC. (US) | 1994-11-09 | — | — | EP | claimed |
| US-20040009923-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | DOLLE ROLAND E (US) | 2004-01-15 | — | — | US | disclosed |
| US-6576614-B1 | Administering methyl ketones or closed hemiketal derivatives of aspartic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2003-06-10 | — | — | US | disclosed |
| EP-0623592-B1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | VERTEX PHARMA (US) | 2001-06-27 | — | — | EP | disclosed |
| US-5985838-A | TREATING INFECTIOUS DISEASE, RESPIRATORY DISEASE, INFLAMMATORY CONDITIONS, IMMUNE-BASED DISEASE, AUTO-IMMUNE DISEASE, BONE DISEASE, AND TUMORS | VERTEX PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0623592-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | STERLING WINTHROP INC. (US) | 1994-11-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009923-A1 | Peptide analogs as irreversible interleukin-1beta protease inhibitors | IL1B, IL1A, IL1RN | CASP3 247/4885CASP6 153/4885CASP8 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.